S1914 A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC
Primary Objective: To compare overall survival (OS) in patients with inoperable, early stage non-small cell lung cancer (NSCLC) randomized to stereotactic body radiation therapy (SBRT) with or without atezolizumab.
Secondary Objectives: To compare investigator-assessed progression-free survival (IA-PFS) between the arms. To compare PFS by blinded independent centralized review (BIRC) between the arms in a random subset of patients. To evaluate distant, locoregional, and local failure rates within each treatment arm. To evaluate the frequency and severity of toxicities within each treatment arm.